

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



File copy

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 7/00, 7/01, 15/00, 15/48, 15/85	A1	(11) International Publication Number: WO 94/29437 (43) International Publication Date: 22 December 1994 (22.12.94)
(21) International Application Number: PCT/US94/06415 (22) International Filing Date: 7 June 1994 (07.06.94) (30) Priority Data: 08/073,345 7 June 1993 (07.06.93) US (71) Applicant: UNIVERSITY OF MEDICINE & DENTISTRY OF NEW JERSEY [US/US]; 110 Administration Complex, 30 Bergen Street, University Heights, Newark, NJ 07101-3000 (US). (72) Inventor: DORNBURG, Ralph, C.; 15 Terry Avenue, South River, NJ 08882 (US). (74) Agent: MUCCINO, Richard, R.; P.O. Box 1267, Princeton, NJ 08542 (US).		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: HIGHLY-EFFICIENT, SELF-INACTIVATING, RECOMBINATION-FREE, U3-FREE RETROVIRAL VECTORS		
(57) Abstract <p>The present invention pertains to recombinant retrovirus vectors having a U3-free 5' LTR, a partially deleted 3' LTR, all essential cis-acting sequences for replication, an internal promoter recognizable by a selected host cell, and a non-retroviral gene under the control of the recognized promoter wherein (a) the U3-free 5' LTR is positioned 5' of the non-retroviral gene and has a transcriptional promoter and enhancer different from that of the original retroviral promoter and enhancer replacing the original U3 region of the 5'LTR; (b) the partially deleted 3' LTR is positioned 3' of the non-retroviral gene and has no U3 sequences except for those required at the attachment site for viral integration; (c) an exogenous polyadenylation addition signal sequence recognized by the selected host cell and positioned on the vector 3' to the 3'LTR viral integration site; and (d) the internal recognized promoter is positioned adjacent to the non-retroviral gene on the vector to permit expression of the non-retroviral gene in the host cell; whereby the vector can produce progeny virus in a helper cell with the progeny virus being capable of infecting the selected host cell and forming a provirus in the host cell, with the non-retroviral gene being expressible in the host cell, but the provirus in the host cell will be replication incompetent even in the presence of a helper virus.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

5

10

**HIGHLY-EFFICIENT, SELF-INACTIVATING,
RECOMBINATION-FREE, U3-FREE RETROVIRAL VECTORS**

15

BACKGROUND OF THE INVENTION

Field of the Invention

20

25

This invention relates to recombination-free, highly-efficient retroviral vectors that self-inactivate after one round of retroviral replication. The present vectors allow cell-type specific gene expression from tissue specific promoters and enhancers. The recombination-free retroviral vectors eliminate risks of downstream activation of cellular proto-oncogenes (tumorigenesis) that can occur with conventional vectors. This invention also relates to a retrovirus produced by the recombinant retrovirus vector and a host cell containing the provirus of the present invention.

30

Description of the Background

35

The disclosures referred to herein to illustrate the background of the invention and to provide additional detail with respect to its practice are incorporated herein by reference. For convenience, the disclosures are referenced in the following text and respectively grouped in the appended bibliography.

40

Retroviral vectors are the most efficient tools to introduce genes into vertebrate cells. Clinical experiments have been conducted to use retrovirus vectors

to cure a genetic disease in humans (adenosine deaminase (ADA) deficiency). Besides correcting inborn errors of metabolism, gene therapy is also being tested in clinical trials to cure cancer and various other diseases (Science 1992, Vol. 258, pp. 744-746).

5

Retroviral vectors are basically retroviral particles that contain a crippled viral genome in which all viral protein coding sequences have been replaced with the gene(s) of interest. As a result, such viruses cannot further replicate after one round of infection without the help of a helper virus. Retroviral vector particles are produced by helper cells (Figure 1). Such helper cells contain plasmid constructs which express all retroviral proteins necessary for particle production and replication. After the introduction (transfection) of the retroviral vector genome into such helper cells, the vector genome (an RNA genome) is encapsidated into virus particles (due the presence of specific encapsidation sequences). Virus particles are released from the helper cell carrying a genome containing only the gene(s) of interest (Figure 1). After infection of a fresh target cell, the RNA genome is reverse transcribed into DNA. The DNA copy is integrated into the host genome (Figure 2A). The integrated viral DNA is called the provirus. In the last decade, several retroviral vector systems, derived from chicken or murine retroviruses, have been developed for the expression of various genes (for reviews see Temin, 1987; Gilboa, 1990).

Retroviral vectors have several limitations. For example, one major concern is the possible activation of proto-oncogenes as a result of the integration of the vector into the target cell genome. The activation of proto-oncogenes which is mediated by the viral LTR (Long Terminal Repeats) promoter and enhancer can lead to the malignant transformation (cancer) of the infected cell. Another problem with current retroviral vectors is regulated gene expression. Due to the presence of the retroviral LTR promoter and enhancer, it is impossible to design reliable vectors for tissue specific gene expression.

To avoid these two shortcomings, retroviral vectors have been developed from murine leukemia virus (MLV) and spleen necrosis virus (SNV) that self-inactivate after one round of retroviral replication (Yu et al, 1986; Dougherty and Temin, 1987; United States patent no. 4,980,289 to Temin et al.). This has been achieved by deleting parts or almost all sequences of the retroviral U3 region of the right LTR (Figure 2B). As a result of the mechanism of the retroviral life-cycle, after one round of replication, a retroviral provirus is formed that does not contain LTR promoters.

However, in the case of MLV derived vectors, the efficiency of gene transduction was about four orders of magnitude less than that of a vector with two complete LTRs. In the case of SNV, efficiency of gene transduction decreased only about tenfold. However, detailed investigations revealed that the U3-region of the right LTR was reconstituted in the helper cell (Olson et al., 1992). This reconstitution of the U3-region was the result of recombination (or gene conversion) of the vector with retroviral sequences present in the helper cell or in the other LTR.

To prevent such recombination events, new SNV-derived helper cells were constructed that express retroviral particle proteins from promoters and enhancers different from those present in the retroviral genome. Such new helper cells were termed DSN cells. DSN cells contain two separate plasmids for the expression of gag-pol and env proteins (Dougherty and Temin, 1989). One plasmid contains the gag-pol gene of SNV which is expressed from the CMV promoter. The other plasmid contains the envelope gene unit of SNV which is expressed from the RSV promoter. Experiments performed with these new helper cells and SNV derived U3-minus vectors (e.g., pJD220SVHY, see Figure 3) revealed that the frequency of the recombination event(s) leading to a vector with two wild-type LTRs was markedly reduced. However, vectors containing two wild-type LTRs were still recovered from transfected DSN helper cells (Dougherty et al., 1989). This finding showed that the (unaltered) U3-region of the left LTR of the vector construct can also serve as a template for the recombination (or gene conversion) event resulting in the reconstitution of the U3-region of the right LTR.

BRIEF DESCRIPTION OF THE FIGURES

FIGURE 1 is a diagram illustrating retroviral helper cells producing recombination-free, self-inactivating retroviral vectors.

FIGURE 2 is a diagram illustrating retroviral vector replication.

FIGURE 3 is a diagram illustrating retroviral vectors derived from spleen necrosis virus (SNV).

FIGURE 4 is a diagram illustrating the nucleotide sequences at the junction of the cytomegalovirus (CMV) with spleen necrosis virus sequences as present in the pPO111 and pPO115 vector series.

5

SUMMARY OF THE INVENTION

10 The present invention pertains to a recombinant retrovirus vector having a U3-free 5' LTR, a partially deleted 3' LTR, all essential cis-acting sequences for replication, an internal promoter recognizable by a selected host cell, and a non-retroviral gene under the control of the recognized promoter wherein:

15 (a) the U3-free 5' LTR is positioned 5' of the non-retroviral gene and has a transcriptional promoter and enhancer different from that of the original retroviral promoter and enhancer replacing the original U3 region of the 5'LTR;

(b) the partially deleted 3' LTR is positioned 3' of the non-retroviral gene and has no U3 sequences except for those required at the attachment site for viral integration;

20 (c) an exogenous polyadenylation addition signal sequence recognized by the selected host cell and positioned on the vector 3' to the 3' LTR viral integration site; and

(d) the internal recognized promoter is positioned adjacent to the non-retroviral gene on the vector to permit expression of the non-retroviral gene in the host cell;

25 whereby the vector can produce progeny virus in a helper cell with the progeny virus being capable of infecting the selected host cell and forming a provirus in the host cell, with the non-retroviral gene being expressible in the host cell, but the provirus in the host cell will be replication incompetent even in the presence of a helper virus.

30

The present invention also pertains to a retrovirus produced by the recombinant retrovirus vector and a host cell containing the provirus of the present invention.

35

DETAILED DESCRIPTION OF THE INVENTION

5 This invention relates to recombination-free, highly-efficient retroviral vectors that self-inactivate after one round of retroviral replication. The vectors allow cell-type specific gene expression from tissue specific promoters and enhancers and eliminate risks of downstream activation of cellular proto-oncogenes (tumorigenesis) that can occur with conventional vectors. The present self-inactivating vectors eliminate the problems of recombination and give rise to high
10 gene transfer efficiency, up to 1,000 fold higher than that of existing self-inactivating vectors. The vectors described herein are derived from spleen necrosis virus but vector modification may be made with any retroviral vector leading to similar results. Thus, the novel vectors have a high potential for use in human gene therapy and in other gene transfer applications in which the cell-type specific gene
15 expression is required, e.g., tissue specific gene expression in transgenic animals.

To eliminate vector recombination and improve the efficiency of gene transduction, two modifications were made to a self-inactivating retroviral vector. First, the U3 region of the left LTR was replaced by the immediate early
20 gene promoter and enhancer of the cytomegalovirus (CMV, Figures 3 and 4). This promoter was shown to be the strongest among a series of promoters tested for gene expression in a large variety of cell-types including the SNV promoter in D17 cells. In order not to abolish retroviral replication, the substitution of the U3 promoter by the CMV promoter was done in such a way that initiation of transcription started at
25 the beginning of R as in the wild-type virus. In particular, if RNA transcription is initiated upstream of the original initiation site, first strand cDNA synthesis would result in a cDNA product abolishing replication. It may be transferred and hybridize to the R-region of the second RNA molecule. However, such a cDNA most probably could not function as a primer, since the immediate 3' nucleotides of
30 that cDNA would not find homologous sequences for hybridization. Since the precise initiation of transcription was difficult to predict, three constructs (designated as pPO111-R1, pPO111-R2, and pPO111-R3) were made in which variable amounts of the U3 nucleotides upstream of the first nucleotide of R were retained (Figures 3 and 4). The function as well as frequencies of recombination of these constructs was tested as described earlier (Dornburg and Temin, 1988; Olson
35 et al., 1992) and as described below. Second, the encapsidation region, as present in previous SNV derived vectors, was extended. Such additional sequences increase the efficiency of encapsidation of the vector genome into retroviral particles (Embretson and Temin, 1987).

In one embodiment of the present invention, the vector is a recombinant retrovirus vector having a normally replication incompetent retrovirus gene sequence with a foreign eukaryotic gene. The retrovirus gene sequence is prepared with a deficiency in the retrovirus promoter so that the vector can still produce progeny virus in a helper cell, with the progeny virus being capable of infecting a selected eukaryotic host cell, forming a provirus, and expressing the eukaryotic gene in the host cell, but the provirus will be defective in the retrovirus promoter sequence. Preferably, the vector is a recombinant plasmid. In another embodiment, a foreign internal promoter is positioned adjacent to the foreign eukaryotic gene on the vector to permit expression of the foreign eukaryotic gene in the eukaryotic host cell without initiating retroviral provirus gene expression. In one form, the reading direction of the foreign promoter is inverted relative to the normal reading direction of the retrovirus gene sequence, and a foreign 3' RNA processing sequence is positioned on the side of the foreign eukaryotic gene sequence which is opposite to the foreign promoter. In another embodiment, the retrovirus is a normally replication incompetent retrovirus of the type having a retrovirus portion and a foreign eukaryotic portion, the retrovirus portion having a deficient promoter portion, such that the virus is capable of infecting a eukaryotic host cell, forming a provirus, and expressing a eukaryotic protein coded for by the foreign eukaryotic portion in the host cell, but the provirus will be defective in a retrovirus promoter such that retroviral provirus gene expression doesn't take place in the host cell.

The present invention allows one to select a eukaryotic gene of interest, insert the gene into a vector designed in accordance with the present invention, transfect a helper cell with the vector, harvest virus stock from the helper cell, use the harvested progeny virus to infect a target cell, and have the proviruses which are formed in the target cells express the inserted eukaryotic gene without expressing any retroviral proteins. Since there is no retroviral promoter that is active on the provirus, endogenous helper proteins cannot trigger production of a virus from the provirus. Since there is no retroviral promoter in the provirus, the provirus cannot provide a retrovirus signal that might trigger the host cell to act in an unintended way. The lack of retroviral promoter stops production of retroviral RNA. This system renders much more likely the acceptability of recombinant retrovirus as drugs for vertebrates.

In the present invention, the enhancer and the promoter sequences of the retrovirus present at U3 in SNV have been deleted from the right side of the

DNA sequence in the plasmid vector (3'LTR). Only the sequences required at the attachment site for viral integration in the 3' LTR are present. The U3 5' LTR has a transcriptional promoter and enhancer different from that of the original retroviral promoter and enhancer to replace the original U3 region of the 5'LTR. The total
5 lack of homology in the two U3 sequences prevent recombination. The U3 sequence normally present in the 5' LTR has been reported to be used as a template to repair a partially deleted U3 sequence in the 3' LTR. By eliminating the U3 sequence in the 5' LTR, the template for repair of the partially deleted U3 sequence in the 3' LTR is also eliminated. The vector DNA is used to transfect
10 helper cells in a conventional manner. Because transcription from the vector begins at R on the left side, and because the promoter on the left side is not defective, virus can be harvested from the transfected helper cell in the conventional manner. Target cells can then be infected with the harvested virus. Since the right side U3 supplies the coding sequences for both U3 segments in the resulting provirus, the
15 transcriptional promoter which was originally deleted on one side of the plasmid DNA shows up as being deleted from both sides in the resulting provirus. The vector therefore permits a stock of the retrovirus progeny virus to be grown up, yet will not permit further replication after one infection cycle.

20 If an internal promoter is not inserted, there will be no promoter to produce the desired foreign eukaryotic gene expression. Preferably such a promoter is positioned immediately adjacent to the foreign eukaryotic of interest so that no intervening retrovirus genes RNA is expressed. Because deletion of most of the U3 in SNV resulted in a loss of correct 3' end processing of viral RNA, even
25 though AAUAAA was still present, a polyadenylation site was added to the vector. Moreover, problem recombinations are unlikely because the U3 sequences in the vector are not homologous.

Abbreviations used in the present invention are as follows: pro-
30 promoter; enh-enhancer; PBS-primer binding site for DNA synthesis; PPT-polypurine track for DNA synthesis; E-encapsidation sequences for RNA packaging; attR+-a sequence that will form the right side of the attachment site relating to integration; attL+-the sequence that will form the left side of the attachment side relating to integration; attL+-the deletion of the original provirus
35 left-side attachment site; and attR+-the deletion of the original right side attachment site.

The term "oligonucleotide" as used herein refers to primers, probes, oligomer fragments to be detected, oligomer controls, and unlabeled blocking

oligomers. Oligonucleotide are molecules comprised of two or more deoxyribonucleotides or ribonucleotides. The term "primer" as used herein refers to an oligonucleotide, preferably an oligodeoxyribonucleotide, either naturally occurring such as a purified restriction digest or synthetically produced, which is capable of acting as a point of initiation of synthesis when subjected to conditions in which synthesis of a primer extension product, which is complementary to a nucleic acid strand, is induced, *i.e.*, in the presence of nucleotides, an agent for polymerization such as a DNA polymerase, and a suitable temperature and pH. The primer must be sufficiently long to prime the synthesis of extension products in the presence of the polymerization agent.

FIGURE 1 is a diagram illustrating retroviral helper cells producing recombination-free, self-inactivating retroviral vectors. FIGURE 1A shows cells (preferentially D17 cells=canine cells) transfected with two different plasmids expressing the retroviral gag-pol and env genes, respectively. These genes are expressed from promoters and enhancers different from the vector long terminal repeat LTR promoter and enhancer. FIGURE 1B shows that after the transfection of the retroviral vector genome into such helper cells, viral particles are produced that contain the RNA vector genome with the gene of interest.

FIGURE 2 is a diagram illustrating retroviral vector replication. FIGURE 2A shows an example of a conventional retroviral vector provirus as present in the helper cell shown at the top. This vector contains wild-type long terminal repeats with full-length U3, R, and U5 regions. RNA transcription yields the RNA transcript shown below. This RNA contains an encapsidation sequence (E) and all other cis-acting sequences necessary for replication (pbs = primer binding site, ppt = polypurine tract). After infection of a fresh target cell the retroviral genome is reverse transcribed into a double-stranded DNA copy. During this process, the U3-region which contains the retroviral promoter and enhancer and which is present at the 3' end of the RNA genome is duplicated and attached to the 5' end of the DNA copy. In a similar way, the U5 region, present only at the 5' end of the RNA genome, is also duplicated and attached to the 3' end of the DNA copy. The double-stranded DNA copy is integrated into the genome of the infected cell. Due to the presence of two long terminal repeats which contain the retroviral enhancer and promoter, tissue specific gene expression cannot be obtained. Further, the downstream enhancer and promoter can activate gene expression of genes located downstream of the integrated provirus (indicated by an arrow). FIGURE 2B illustrates the principle of a self-inactivating retroviral vector. The vector present in the helper cell is shown at the top. This vector is almost identical

to the one shown above. However, the long terminal repeat at the right side has been modified in the following way: most of U3-sequences including the promoter and enhancer sequences have been deleted. Maintenance of some U3-sequences that form the attachment site (att) is essential for the efficient integration of the vector genome. The RNA transcribed from the U3-minus vector virus does not contain the retroviral promoter and enhancer. Thus, after one round of retroviral replication, a promoter-less retroviral provirus is formed. Genes can be expressed from internal tissue-specific promoters (pro).

FIGURE 3 is a diagram illustrating retroviral vectors derived from spleen necrosis virus (SNV). The SNV genome (provirus) is shown at the top. An example of a standard retroviral derived from SNV is shown below (pJD214HY). In all SNV-derived standard vectors, the protein coding regions (gag-pol and env, the region from SalI to the 3' end of env) have been replaced with the gene(s) of interest (in pJD214HY with hygromycin resistance gene, referred to as hygro). pJD220SVHY is a first generation self-inactivating retroviral vector in which the retroviral promoter and enhancer of the right LTR have been deleted (designated as U3 minus; for more details, see Figure 2B). To increase efficiency of replication, the polyadenylation sequence of simian virus 40 (SV40ter) has been inserted downstream of the U3-minus LTR. To avoid problems of recombination of first generation U3-minus vectors in the pPO111 vectors, the U3 region of the left LTR has been almost completely deleted (except a few nucleotides to guarantee correct initiation of transcription) and substituted for the immediate early promoter and enhancer of the human cytomegalovirus (CMV, for more details, see also Figure 4). Further, this second generation, U3-free vector contains additional retroviral sequences (from SalI to EagI) to increase the efficiency of encapsidation. A universal, second generation U3-free vector (pPO115-R1) contains a multiple cloning site replacing the promoter (SV40pro) and hygromycin B resistance gene (hygro) as present in pJD220SVHY and pPO111-R1 (from EagI to ClaI). The multiple cloning site has been derived from pBluescript II (EagI to ClaI) and allows the easy insertion of various genes and promoters to give new retroviral vectors.

FIGURE 4 is a diagram illustrating the nucleotide sequences at the junction of the cytomegalovirus (CMV) with spleen necrosis virus sequences as present in the pPO111 and pPO115 vector series. An excerpt of the SNV genome showing the TATA box and initiation of transcription is shown at the top. The SacI site downstream of the TATA box of the CMV immediate early promoter (shaded sequence) was used for cloning to connect the CMV promoter and enhancer

to the SNV sequences. pPO111-R2 and pPO111-R3 are 3 or 9 nucleotides shorter than pPO111-R1, respectively.

5 The function of the new vectors was tested in a tissue culture system as follows and as described earlier (Olson et al., 1992): The new vector constructs pPO111-R1, pPO111-R2, and pPO111-R3 were transfected into helper cells. In parallel, the retroviral vectors pJD214HY, a standard retroviral vector with two complete wild-type LTRs, and pJD220SVHY, the first generation self-inactivating vector from which the new vectors have been derived (Figure 3), were also
10 transfected into helper cell-lines. Transfected cells were selected for hygromycin resistance and cell-lines were established. These resulting helper cell lines are designated as step 1 cells. Virus was harvested from confluent step 1 cultures and fresh helper cells were infected. The infected helper cells were termed step 2 cells. Virus titers were determined (Table 1). We show that the new vectors pPO111-R1
15 to pPO111-R3 were more efficient than pJD220SVHY. They were almost as efficient as a vector with two wild-type LTRs (pJD214HY).

 To test for recombination, virus particles were harvested from confluent step 2 cell cultures (mass infection) and fresh D17 cells were infected.
20 Detection of hygromycin resistant colonies indicates that recombination reconstituted the U3 region: due to the lack of control sequences in RNA transcripts derived from completely U3-minus proviruses, such vectors are not further passaged by retroviral proteins. Thus, only vectors with complete, repaired LTRs are transferred to new target cells. We found that pJD220SVHY was further
25 passaged with high efficiency confirming earlier findings (Olson et al., 1992). The new vectors pPO111-R1 to R3, however, were not further transferred from step 2 helper cells (Table 1). These data show that the new vectors are resistant to recombination events that reconstitute the LTR region.

TABLE 1

EFFICIENCY OF INFECTIVITY AND RECOMBINATION OF SELF-
INACTIVATING RETROVIRAL VECTORS DERIVED FROM SNV

5

VECTOR NAME	VIRUS TITER (CFU)	
	1. INFECTION	2. INFECTION
pJD214HY	6 X 10 ⁵	5 X 10 ⁶
pJD220SVHY	8 x 10 ⁴	1 x 10 ³
10 pPO111-R1	4 x 10 ⁵	0*
pPO111-R2	2.5 x 10 ⁵	0*
pPO111-R1	1.5 x 10 ⁵	0*

* No hygromycin resistant colonies were obtained with pPO111 vectors.

15

The retroviral vectors (see also Figure 3) were transfected into helper cells followed by hygromycin selection. Virus was harvested from confluent cultures and fresh helper cells were infected (referred to as first infection). Infected cells were selected for hygromycin resistance, and virus titers were determined (expressed as colony forming units (CFU) per ml of supernatant medium). Cell-

20 lines were established from infected tissue culture plates which contained more than 1,000 independent hygromycin resistant colonies. Virus was harvested from confluent cell cultures and fresh D17 cells were infected (referred to as second infection). Infected cells were selected for hygromycin resistance and virus titers

25 were determined.

Examples

Materials and Methods

30

Plasmid construction.

The immediate early promoter and enhancer of cytomegalovirus, CMV (a 900 bp Hind3 fragment obtained from plasmid pJDCMV19SV, Dougherty et al., 1990) was cloned into plasmid pRD15 (described in Sheay et al., submitted

35

for publication). The resulting plasmid was termed pPO101. A DNA fragment containing most of the LTR, the encapsidation region, and parts of the gag-pol region of spleen necrosis virus (a Bal1 fragment derived from plasmid pSW253, described by Watanabe and Temin, 1982) was cloned into the blunted Sac1 site of pBluescript II KS. The resulting plasmid was termed pPO102. Plasmid pPO102 was digested with Sac1 and re-ligated after treatment with Klenow polymerase 1 (creation of blunt ends) to eliminate a Sac1 site present in the encapsidation sequence. The resulting plasmid was termed (pPO102-S). Using PCR technology and plasmid pPO102-S as template, three DNA fragments were generated comprising slightly different amounts of the SNV R, U5, and encapsidation region: a DNA fragment termed R1 comprises map units 383 to 986 of the SNV genome, fragment R2 comprises map units 385 to 986, and fragment R3 comprises map units 392 to 986. All PCR primers contained Sac1 recognition sites at their 5' ends. After Sac1 digestion, fragments R1, R2, and R3 were cloned into the Sac1 site of pBluescript II KS. The resulting plasmids were termed pPO103-R1, pPO103-R2 and pPO103-R3, respectively. Fragments R1 to R3 were isolated from such plasmids and cloned into the Sac1 site of pPO101. The resulting plasmids were termed pPO104-R1, pPO104-R2, and pPO104-R3, respectively.

Plasmid pJD220SVHY (Dougherty and Temin, 19986) was digested with Ssp1 and Sac1. After Klenow poll treatment, a linker coding for the recognition site of the restriction enzyme Bgl2 was ligated. This procedure removed the left LTR promoter, and all of the encapsidation sequences present in this vector. The resulting plasmid was termed pPO106. DNA fragments derived from plasmids pPO104-R1, pPO104-R2, and pPO104-R3 comprising the CMV promoter, R, U5, and the encapsidation sequence (Bgl2 fragments) were isolated and inserted into plasmid pPO106 digested with Bgl2. The resulting plasmids were termed pPO111-R1, pPO111-R2, and pPO111-R3, respectively. The universal retrovirus vectors pPO115-R1 and pPO115-R2 were made by replacing the SV40 promoter and hygromycin B phosphotransferase gene of pPO111-R1 and pPO111-R2 (Eag1 to Cla1 fragment) with the multiple cloning site (Eag1 to Cla1) of pBluescript II KS.

DNA sequence pPO111-R1 5528 b.p. complete sequence;

5 CAGATCTGAGCTTGCCATTGCATACGTTGTATCCATATCATAATGTACATTTATATTGGCTCA
TGTCACACATTACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGG
GTCAATTAGTTCATAGCCCATATATGGAGTTCGGCGTTACATAACTTACGGTAAATGGCCCGCTG
10 GCTGACCGCCCAACGACCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCA
ATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTACGGTAACTGCCACTTGGCAGTACA
TCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCTGGC
ATTATGCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATC
15 GCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACG
GGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTGTTGGCACC AAAATCAACGGG
ACTTTCCAAAATGTCGTAAACAACCTCGCCCATTGACGCAAAATGGGCGGTAGGCGTGTACGGTGG
GAGGTCTATATAAGCAGAGCTCATCTCTGCTCGGGGTCGCCGCTCCTGCACATTGTTGTTGTGAC
GTGCGGCCAGATTGCAATCTGTAATAAACTTTTTTTTCTGAATCCTCAGATTGGCAGTGAG
20 AGGAGATTTTGTTCGTGGTGTTCCTGGCCTACTGGGTGGGCGCAGGGATCCGGACTGAATCCGT
AGTACTTCGGTACAACATTTGGGGGCTCGTCCGGGATACCTCCCCATCGGCAGAGGTGCCAACT
GCTTCTTCAACTTTCTTCGAACTCCGGCGCCGGTGAGTTAAGTACTTGATTTTGGTACCTCGCG
AGGGTTTGGGAGGATCGGAGTGGTGGCGGACGCTGCCGGGAAGCTCCACCTCGGCTCAGCAGGG
GACGCCCTGACCTGAGCTCGAATTGAGATCTTGTGGTATCTGATTGTTGTTGAGCCGTCCTAAG
25 ACGGTGATACTAAGTCGTGGCTTGTGTGTTTGTGTTGCTTGTGTTGTTGCTCGTTTGTGCA
CAGCGCCTTGCGAATTGGTGTACCCACACCGCGCGCTTGCGAATAATACTTTGGAGAGCCTTTT
GCCTCCAGTGCTTCCGTCTGACTCGTCTCTCTCCCTCTCCGGCCGGGAGAGCTCGCCCGGG
GATCCTCTAGTATGGTGCACCTCTCAGTACAATCTGCTCTGATGCCGATAGTTAAGCCAGTATAC
ACTCCGCTATCGCTACGTGACTGGGTGATGGCTGCCGCCGACACCGCCAAACCCGCTGACGC
30 GCCCTGACGGGCTTGTCTGCTCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCT
GCATGTGTGAGAGGTTTTCCCGTCTATCACCAGAAACGCGCAGGCGAGCTGTGGAATGTGTGTCAG
TTAGGGTGTGAAAGTCCCGAGGCTCCCGCAGCAGGAGATGCAAAAGCATGCATCTCAATTA
GTCAGCAACCAAGGCTCCCGCAGGCGAGAGTATGCAAAAGCATGCATCTCAATTAAGTCAGCAACC
ATAGTCCCGCCCTAACTCCGCCCATCCCGCCCTAACTCCGCCCAAGTTCCGCCCATTTCCCGCC
35 CCATGGCTGACTAATTTTTTTTATTTATGAGAGGCGCAGGCGGCTCGGCCCTGAGCTATTCC
AGAAGTAGTGAGGAGGCTTTTTTGGAGGCTTAGGCTTTTGCAAAAAGCTCTAGAGTCGACCTGCA
GCCCAAGCTGATCCCGGGGGCAATGAGATATGAAAAAGCCTGAACCTACCGCGAGCTGTGCGA
GAAGTTCTGATCGAAAAGTTCGACAGCGTCTCCGACCTGATGCAGCTCTCGGAGGGCGAAGAT
40 CTGCTGCTTTGAGCTTCGATGTAGGAGGGCGTGATATGCTCGGGTAATAGCTGCGCCGAT
GGTTTCTACAAAGATCGTTATGTTTATCGGCACCTTGCAATCGGCCGCGCTCCCGATTCCGGAAGT
GCTTGACATTGGGGAATTCAGCGAGAGCCTGACCTATTGCATCTCCCGCGTGCACAGGGTGTCA
CGTTGCAAGACCTGCCTGAAACCGAATGCCCGCTGTTCTGCAGCCGGTCCGGAGGCATGGAT
GGCATCGCTGCCGCCGATCTTAGCCAGACGAGCGGTTCCGGCCATTCCGACCGCAAGGAATCGG
45 TCAATACACTACATGGCGTGATTTATATGCGCGATTGCTGATCCCATGTGTATCACTGGCAAA
CTGTGATGGACGACACCGTCAGTGGTCCGTGCGCAGGCTCTCGATGAGCTGATGCTTTGGGCC
GAGGACTGCCCCGAAGTCCGGCACCTCGTGACGCGGATTTCCGCTCCAACAATGCTCTGACGGA
CAATGGCCGATACAGCGGTCAATTGACTGGAGCGAGGCGATGTTCCGGGATTCCCAATACGAGG
TCCCAACATCTTCTTGGAGGCGGTGGTTGGCTTGTATGGAGCAGCAGCGCGCTACTTCGAG
50 CCGAGGCAATCCGGAGCTTGACGAGTACGCCCGGCTCCGGGCGTATATGCTCCGCATTGGTCTTGA
CCAATCTATCAGAGCTTGGTTGACGGCAATTTGATGATGCAGCTTGGGCGCAGGGTGCATGGG
ACGCAATCGTCCGATCCGGAGCCGGGACTGTCCGGCGTACACAAATCGCCCGCAGAACCGCGGCC
GTCTGGACCGATGGCTGTGTAAGTACTCGCCGATAGTGGAAACCGACGCCCGACCACTCGTGG
GATCAGCTTGGCACTGGAATTAATCTCATGTTTACAGCTTATCATCGATAAGCTCTAGGTCAA
55 TGGTTTGACCAGAACATACAAGAGCAGTGGGGAATGTGGGAGGGCTCGAGGTCCGGGTCGCCGT
CCTACACATTTGTTGTGACGTGCGGCCAGATTCGAATCTGTAATAAAACCTTTTTTAACTG
AATCCTCAGATTGGCAGTGAGAGGAGATTTGTTGCTGGTGTGGCTGGCCTACTGGGTGGGCGC
AGGGATCGATCCAGACATGATAAGATACATTGATGAGTTTGACAAACCAACTAGAATGCAAT
GAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTAAGCTGC
AATAAACAAGTTAACAACAACAAATTGCATTCTTTTATGTTTCAGGTTACGGGGAGGTGTGGGA
60 GGTTTTTAAAGCAAGTAAACCTCTACAAATCAAGCTGATCCCTGCCGCTTTCGGTGAT
GACGGTGAACCTCTGACACATGCAGCTCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGC
CGGGAGCAGACAAGCCCGTCAGGGCGCTCAGCGGGTGTGGCGGGTGTGGGGCGCAGCCATGA
CCCGTACGATAGCGATAGCGGAGTGTACTGGCTTAACATGCGGCATCAGAGCAGATTGTAC

TGAGAGTGCACCATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAAATACCGCATCAGG
 CGCTCTTCCGCTTCTCGCTCACTGACTCGCTGCGCTCGGTGCTTCGGTGCAGGAGCGGTATC
 AGCTCACTCAAAGGCGGTAAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAATATGT
 GAGCAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGGTTCCTGGCGTTTTTCCATAGG
 5 CTCCGCCCCCTGACGAGCATCAAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGG
 ACTATAAAGATACCGGCGTTTCCCTGGAAGCTCCCTCGTGCCTCTCCTGTTCCGACCCCTGC
 CGCTTACCGGATACCTGTCCGCCCTTCTCCCTTCGGGAAGCGTGGCGCTTTCATAGCTCACGC
 TGTAGGTATCTCAGTTGCGGTGAGGTGCTCGCTCCAAGCTGGGCTGTGTGCAGAACCCCGCT
 TCAGCCCGACCGCTGCGCCTTATCCGGTAATATCGTCTTGAGTCCAACCCGGTAAGACACGACT
 10 TATCGCCACTGGCAGCAGCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACA
 GAGTTCTTGAAGTGGTGGCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCT
 GCTGAAGCCAGTTACCTTCGGAAGAGTGGTAGCTCTTGATCCGGCAACAAACACCGCTG
 GTAGCGGTGGTTTTTTGTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGAT
 CCTTGATCTTTTCTACGGGCTGACGCTCAGTGGAAACGAAACTCAGGTTAAGGGATTTTGGT
 15 CATGAGATTATCAAAAGGATCTTCACCTAGATCCTTTAAATTAATAATGAAGTTTTAAATCAA
 TCTAAAGTATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATC
 TCAGCGATCTGTCTATTTCTGTTTATCCATAGTTGCGCTGACTCCCGCTGCTGAGATAACTACGAT
 ACGGGAGGGCTTACCATCTGGCCCCAGTGTGCAATGATACCGCAGACCCACGCTCACCGGCTC
 CAGATTTATCAGCAATAAACCGCCAGCCGGAAGGCGCAGCAGAGTGGTCTGCACTTTA
 20 TCCGCCCTCCATCCAGTCTATTAATTGTTGCCGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAG
 TTTGCGCAACGTTGTTGCCATTGCTGCAGGCATCGTGGTGCACGCTCGTCTGTTGGTATGGCTT
 CATTCAGCTCCGCTTCCCAACGATCAAGGCGAGTTACATGATCCCATGTTGTGCAAAAAGCG
 GTTAGCTCCTTCGGTCTCCGATCGTTGTGAGAAGTAAGTTGGCCGAGTGTATCACTCATGGT
 TATGGCAGCACTGCATAATTCTCTTACTGTGATGCCATCCGTAAGATGCTTTTCTGTGACTGGTG
 25 AGTACTCAACCAAGTCATTCTGAGAATAGTGTATCGCGCAGCCGAGTTGCTCTTGCCCGCGCTCA
 ACACGGGATAATACCGCGCCACATAGCAGAACTTTAAAGTGTCTCATTTGGAACCGTTCTTC
 GGGGCGAAAACCTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGAC
 CCAACTGATCTTCAGCATCTTTACTTTACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAA
 AATGCCGCAAAAAGGGAATAAGGGCGACACGGAATGTTGAATACTCATACTCTTCTTTTCA
 30 ATC

DNA sequence pPO111-R2 5525 b.p. complete sequence;

35 CAGATCTGAGCTTGCCATTGCATACGTTGTATCCATATCATAATATGTACATTTATATTGGCTCA
 TGTCCAACATTACCGCATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGG
 GTCATTAGTTCATAGCCATATATGAGTTCGCGTTACATAACTACGGTAAATGGCCCGCTG
 GCTGACCGCCCAACGACCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCA
 ATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTACGGTAAACTGCCCACTTGGCAGTACA
 40 TCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCTGGC
 ATTATGCCAGTACATGACCTTATGGGACTTTCTACTTGGCAGTACATCTACGTATTAGTCATC
 GCTATTACCATTGGTATGCGGTTTTGGCAGTACATCAATGGCGTGGATAGCGGTTGACTCACG
 GGGATTTCCAAGTCTCCACCCATTGACGTCAATGGGAGTTGTTTTGGCACCAAAATCAACGGG
 45 ACTTTCCAAAATGTCGTAACAACTCCGCCCATGACGCAAAATGGCGGTAGGCGGTACGGTGG
 GAGGTCTATATAAGCAGAGCTCTCTTCTCGGGTCCCGCTCCTGCACATTGTTGTTGTGACGTG
 CGGCCAGATTGCAATCTGTAATAAACTTTTTTTTTCTGAATCCTCAGATTGGCAGTGAGAGG
 AGATTTTGTTCGTGGTGTGCTGGCCTACTGGGTGGGCGCAGGGATCCGGACTGAATCCGTAGT
 ACTTCGGTACAACATTTGGGGCTCGTCCGGGATACCCTCCCATCGGCAGAGGTGCCAAGTGT
 50 TCTTCAACTTTCTTCAACTCCGGCGCCGGTGAAGTAACTTGTATTTGGTACCTCGCGAGG
 GTTTGGGAGGATCGGAGTGGTGGCGGACGCTGCCGGAAGCTCCACCTCCGCTCAGCAGGGGAC
 GCCCTGACCTGAGCTCGAATTCAGATCTTGTGGTATCTGATTGTTGTGAGCCGTCCTAAGACG
 GTGATACTAAGTCGTGGCTTGTGTTGTTGTTGCTTGTGTTGTTGCTCGTCTTGTGACAG
 CGCCTTGGCAATTTGGTGTACCCACACCGCGCGCTTGCGAATAACTTTGGAGAGCCTTTTGC
 55 TCCAGTGTCTTCGCTGTGACTCGTCTCTCTCTCTCCGCGCGGAGAGCTCGCCCGGGAT
 CCTCTAGTATGGTGCACCTCTCAGTACAATCTGCTCTGATGCCGATAGTAAAGCAGTATACACT
 CCGCTATCGCTAGTGAAGTGGTCTGCTGCGCCCCGACACCGCAACACCCGCTGACGCGCC
 CTGACGGGCTTGTCTGCTCCCGCATCCGCTTACAGACAAGCTGTGACCGCTCTCGGGAGCTGCA
 TGTGTACAGGTTTTACCGTCATCACGAAACGCGCAGGCAGCTGTGGAATGTGTGTCAGTTA

GGGTGTGGAAAGTCCCAGGCTCCCAGCAGGCAGAAAGTATGCAAAGCATGCATCTCAATTAGTC
AGCAACCAAGGCTCCCAGCAGGCAGAAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATA
GTCCCGCCCTAACTCCGCCATCCGCCCTAACTCCGCCAGTTCGCCCATTTCTCCGCCCA
5 TGGCTGACTAATTTTTTATTTATGCAGAGGCCAGGCCGCTCGGCTCTGAGCTATCCAGA
AGTAGTGAGGAGGCTTTTTGGAGGCTAGGCTTTGCAAAAAGCTCTAGAGTCGACCTGCAGCC
CAAGCTGATCCCCGGGGCAATGAGATATGAAAAGCCTGAAGTCAACCGGACGCTGTGAGAA
GTTTCTGATGCAAAAGTTCGACAGCGTCTCCGACCTGATGCAGCTCTCGAGGGCGAAGAATCTC
GTGCTTTCAGCTTCGATGTAGGAGGGCGTGGATATGTCCTGCGGGTAAATAGCTGCGCCGATGGT
10 TTCTACAAAGATCGTTATGTTATCGGCACCTTGATCGGCCGCGCTCCGATTCGGGAAGTGCT
TGACATTGGGGAATTGAGCAGAGGCTGACCTATTGCATCTCCGCCGTCACAGGGGTGCACGT
TGCAAGACCTGCTGAAACCGAACTGCCCGCTGTTCTGCAGCCGGTCGCGGAGGCCATGGATCGG
ATCGCTCGGCCGATCTTAGCCAGACGAGCGGGTTCGGCCATTGCGACCGCAAGGAATCGGTCA
ATACACTACATGGCGTATTTCATATGCGCGATTGCTGATCCCATGTGTATCACTGGCAAACTG
TGATGGACGACACCGTCAGTGGTCCGTCGCGCAGGCTCTGATGAGCTGATGCTTTGGCCGAG
15 GACTGCCCGGAAGTCCGGCAGCTGTCGACGCGGATTCGGCTCCAACATGTCCTGACGGAACA
TGGCCGCATAAACAGCGGCTATTGACTGGAGCGAGGCGATGTTCCGGGATTCCTCAATACGAGGTCG
CCAACATCTTCTCTGGAGGGCGTGGTGGCTTGTATGGAGCAGCAGCGGCTACTTCGAGCGG
AGGCATCCGAGCTTCGAGGATCGCCGCGGCTCCGGCGTATATGCTCCGCTTGGTCTTGACCA
ACTCTATCAGAGCTTGGTTGACGGCAATTCGATGATGCAGCTTGGGCGCAGGGTGCATGCGAGC
20 CAATCGTCCGATCCGAGCGGGGACTGTGGGCGTACACAAATCGCCCGCAGAACGCGCGCGTC
TGGACCGATGGCTGTGTAGAAGTACTCGCGATAGTGGAAACCGACGCCCGAGCACTCGTGGGAT
CAGCTTGGCACTGGAATTAATCTCATGTTTGACAGCTTATCATGATAAGCTCTAGGTCAATGG
TTTGACCAGAACATACAAGAGCAGTGGGAATGTGGGAGGGCTCGAGGTGCGGGTCCGCGCTCT
ACACATTTGTTGTGTGACGTGCGGCCAGATTGCAATCTGTAATAAACCTTTTTTAACCTGAAT
25 CCTCAGATTGGCAGTGAGAGGAGATTTGTTCTGTGGTGTGGCTGGCTACTGGTGGGCGCAGG
GATCGATCCAGACATGATAAGATACATTGATGAGTTTGACAAACCACTAGAATGCAGTGAA
AAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTAAGCTGCAAT
AAACAAGTTAAACAACAATTCATTCAATTTATGTTTCAGGTTGAGGGGAGGTGTGGGAGGT
TTTTAAAGCAAGTAAACCTCTACAAATCAAGCTGATCCCTGCTCGCGCTTTCGGTGATGAC
30 GGTGAAAACCTCTGACACATGCAGCTCCCGAGAGCGGTACAGCTTGTCTGTAAGCGGATGCCGG
GAGCAGACAAGCCCGTCAGGGCGGTCAGCGGGTGTGGCGGGTGTGGGCGCGAGCCATGACCC
AGTCAGTACCGATAGCGGAGTGTATCTGGCTTAATATGCGGATCAGAGCAGATTGACTGA
GAGTGACCATATGCGGTGTGAAATACCGCAGATGCGTAAGGAGAAAATACCGCATCAGGCGC
TCTTCGCTTCTCGTCACTGACTCGTGGCTCGGTCGTTGGCTGCGCGAGCGGTATCAGC
35 TCACTCAAAGCGGTAATACGGTTATCCACAGAAACAGGGGATAACGAGGAAAGAACATGTGAG
CAAAAGGCCAGAAAAGCCAGGAACCGTAAAGAGCCGCGTTGCTGGCGTTTTTCATAGGCTC
CGCCCCCTGACGAGCATCACAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCGACAGGACT
ATAAAGATACAGGGGTTTTCCCTTGAAGCTCCCTCGTGGCTCTCTGTTCCGACCTGCGCG
TTACCGGATACCTGTCGCGCTTCTCCCTTCGGGAAGCGTGGCGCTTCTCATAGCTCAGCTGT
40 AGGTATCTCAGTTCGGTGTAGTTCGCTCCAAGCTGGGCTGTGTGACGAAACCCCGTTCA
GCCCCAGCGTCGCGCTTATCCGGTAACATCGTCTTGAGTCCAACCCGGTAAGACAGGACTTAT
CGCCACTGGCAGCAGCACTGGTAACAGGATTAGCAGAGCGAGGTATGATGGCGGTGCTACAGAG
TTCTTGAAGTGGTGGCTAACTACGGCTACACTAGAAGGACAGTATTGGTATCTGCGCTGCT
GAAGCCAGTTACCTTCGAAAAAGAGTTGGTAGCTCTTGATCCGGCAACAAACACCGCTGGTA
45 GCGGTGGTTTTTTGTTTGAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCCT
TTGATCTTTTCTACGGGCTGACGCTCAGTGAACGAAAACTCACGTAAAGGATTTTGGTCAT
GAGATTATCAAAAAGGATCTTACCTAGATCCTTTAAATTAATAAGGATTTTAAATCAATCT
AAAGTATATAGTAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACTATCTCA
GCGATCTGTCTATTTGTTTATCCATAGTTGCCTGACTCCCGCTCGTGATAGTAACACGATACG
50 GGAGGGCTTACCATCTGCCCCAGTGTGCAATGATACCGGAGACCCACGCTCACCGGCTCCAG
ATTTATCAGCAATAAACAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCTGCAACTTATCC
GCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTT
GCGCAACGTTGTTGCCATTGCTGCAGGCATCGTGGTGTACGCTCGTCTTGGTATGGCTTCAT
TCAGCTCCGGTTCCTCAACGATCAAGGCGAGTTACATGATCCCCATGTTGTGCAAAAAGCGGT
55 AGCTCCTTCGGTCTCCGATCGTTGTGAGAAGTAAGTGGCCGAGTGTATCACTCATGGTTAT
GGCAGCACTGCATAATTCTTACTGTGATGCCATCCGTAAGATGCTTTCTGTGACTGGTGAGT
ACTCAACCAAGTCTTCTGAGAATAGTGTATGCGGCGACCGAGTGTCTTGGCCGGCTCAACA
CGGGATAATACCGGCCACATAGCAGAACTTAAAGTGCTCATCATTGGAACCGTTCTCGGG

CGCAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAAACCACTCGTGACCCCA
ACTGATCTTCAGCATCTTTACTTTACCAGCGTTCTGGGTGAGCAAAACAGGAAGGCAAAAT
GCCGCAAAAAGGGAATAAGGGCGACACGGAATGTTGAATACTCATACTCTTCCTTTTCAATC

5

DNA sequence pPO111-R3 5519 b.p. complete sequence;

5
10
15
20
25
30
35
40
45
50
55

CAGATCTGAGCTTGCCATTGCATACGTTGTATCCATATCATAATATGTACATTTATTTGGCTCA
TGTCACATTACGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGG
GTCAATTAGTTCATAGCCCATATATGGAGTTCGGCTTACATAACTTACGGTAAATGGCCCGCTG
GCTGACCGCCCAACGACCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCA
ATAGGGACTTTCATTGACGTCAATGGGTGGAGTATTACGGTAAACTGCCCACTTGGCAGTACA
TCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCTGGC
ATTATGCCAGTACATGACCTTATGGGACTTCTCTACTTGGCAGTACATCTACGTTATAGTCATC
GCTATTACCATGGTGATGGGTTTTGGCAGTACATCAATGGCGTGGATAGCGGTTGACTACG
GGGATTTCCAAGTCTCCACCCCATGACGTCAATGGGAGTTTGTGTTGGCACCACCAATCAACGGG
ACTTTCCAAAATGTCTGAACAACTCCGCCCATGACGCAAAATGGCGGTAGGCGTGTACGGTGG
GAGGTCTATATAAGCAGAGCTCTCGGGGTCCCGCTCTGCACATTGTTGTTGTGACGTGCGGCC
AGATTGCAATCTGTAATAAACTTTTTTTTCTGAATCCTCAGATTGGCAGTGAGAGGAGATT
TGTTCTGGTGTGCTTGGCTACTGGGTGGGCGCAGGGATCCGGACTGAATCCGTAGTACTTCG
GTACAACATTGGGGGCTCGTCCGGATACCTCCCATCGGCAGAGGTGCCAAGTCTTCTTCG
AACTTTCTTGAAGTCCGGCGCGGTGAGTTAAGTACTTGATTTTGGTACCTCGCGAGGTTTGG
GAGGATCGGAGTGGTGGCGGACGCTCGCGGGAAGCTCCACCTCGGCTCAGCAGGGGACGCCCTG
ACCTGAGCTCGAATTCAGATCTTGTGGTATCTGATTGTTGTTGAGCGCTCCCTAAGACGGTGATA
CTAAGTCGTGGCTTGTGTGTTGTTGTTGCTTGTGTTGTTGCTGCTTGTGTCGACAGCGCCTT
GCGAATTGGTGTACCCACACCGCGCGCTTGCGAATAACTTTGGAGAGCCTTTTGCTTCCAGT
GTCTTCGGTCTGTACTGCTCTCTCTCTCTCGGCGGGAGAGCTCGCCCGGGATCCTCTA
GTATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGATAGTTAAGCAGTATACATCCGCTA
TCGCTACGTGACTGGGTGATGGCTCGCGCCGACACCGCCAACACCGCTGACGCGCCCTGACG
GGCTTGTCTGCTCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCGGGAGCTGCATGTGTC
AGAGGTTTTACCGTCAACCGAAACGCGGAGGAGCTGTGGAATGTGTGTCAGTTAGGGGT
GGAAAGTCCCGAGGCTCCCGCAGGCGAGAAGTATGCAAGCATGCATCTCAATTAGTCAGCAAC
CAGGCTCCCGCAGGCGAGAAGTATGCAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCG
CCCTTAACCTCCGCCATCCCGCCCTAATCCGCCAGTTCGCCCATTTCTCGCCCATGGCTG
ACTAATTTTTTTTATGATGAGAGGCGAGGCGGCTCGGCTCTGAGCTATTCAGAAGTAGT
GAGGAGGCTTTTTTGGAGGCTAGGCTTTGCAAAAAGCTCTAGAGTCGACCTGCAGCCCAAGCT
GATCCCGGGGGCAATGAGATATGAAAAGCCTGAATCAACCGCAGCTCTGTCGAGAAGTTCT
GATCGAAAAGTTTCGACAGGCTCTCGACCTGATGCAGCTCTCGGAGGGCGAAGAATCTGTCGTT
TCAGCTTCGATGAGGAGGCGTGGATATGCTCTCGGGTAAATAGCTGCGCCGATGGTTCTAC
40
45
50
55

AAAGATCGTTATGTTATCGGCACTTGCATCGGCGGCTCCCGATTCCGGAAGTCTTGACAT
TGGGCAATTTCAGCGAGAGCTGACCTATTGCATCTCCGCGGTGCACAGGGTGTACGTTGCAAG
ACCTGCCTGAACCGCAACTGCCCGCTGTTCTGACGCGGTGCGGAGGCCATGGATGCGATCGCT
GCGGCGGATCTTAGCCAGACGAGCGGGTTGCGCCCATTCGGACCGCAAGGAATCGGTCAATACAC
TACATGGCGTATTTATATGCGGATTGCTGATCCCATGTGTATCACTGGCAACTGTGATGG
ACGACACCGTCAGTCCGTCGCGCAGGCTCTCGATGAGCTGATGCTTTGGGCGGAGGACTGC
CCCGAAGTCCCGCACCTCGTGCACGCGGATTTGGCTCCAACAATGCTGACGGACAATGGCCG
CATAACAGCGGTCAATTGACTGGAGCGAGGCGATGTTGCGGGATTCCAATACGAGGTGCGCAACA
TCTTCTCTGGAGGCGGTGTTGGCTTGTATGGAGCAGCAGCGCTACTTCGAGCGGAGGCAAT
CCGGAGCTTCGAGGATCGCGCGGCTCGGGCGTATATGCTCCGATTGGTCTTGACCAACTCTA
TCAGAGCTTGGTTGACGCGCAATTCGATGATGACGCTTGGGCGCAGGTCGATGCGACGCAATCG
TCCGATCCGGAGCGGGAATGTCGGGCGTACACAAATCGCCGCGAGAAGCGCGGCTCTGGACC
GATGGCTGTGTAGAAGTACTCGCGGATAGTGAACCGACGCCCGCAGCACTCGTGGGATCAGCTT
GGCACTGGAATTAATCTCATGTTTACAGCTTATCATCGATAAGCTCTAGGTCAATGGTTGAC
CAGAACATACAAGAGCAGTGGGGAATGTGGGAGGGCTCGAGGTGCGGGTCCCGCTCTACACAT
TGTGTTGTGACGTGCGGCCAGATTGCAATCTGTAATAAACTTTTTTAACTGAATCCTCAG
ATTGGCAGTGAGAGGAGATTTGTTGTTGGTGTGGCTGGCTACTGGGTGGGCGCAGGGATCGA
TCCAGACATGATAAGATACATTGATGAGTTTGGACAACCACTAGAATGCAGTGAAAAAAT
GCTTTATTTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATATAAGCTGCAATAAACAA

GTTAACAACAACAAATTGCATTATTTTATGTTTCAGGTTGAGGGGAGGTGTGGGAGGTTTTTA
 AAGCAAGTAAAACTCTACAAATCAAGCTGATCCCTGCCTCGCGCTTTCGGTGATGACGGTGAA
 AACCTCTGACACATGCAGCTCCCGGAGACGGTACAGCTTGTCTGAAGCGGATGCCGGGAGCAG
 ACAAGCCCGTCAGGGCGCGTCAGCGGGTGTGGCGGGTGTGGGGGCGCAGCCATGACCCAGTCAC
 5 GTAGCGATAGCGGAGTGATACTGGCTTAACATATGCGGCATCAGAGCAGATTGTACTGAGAGTGC
 ACCATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAAATACCGCATCAGGCGCTCTTCC
 GCTTCCTCGCTCACTGACTCGCTCGGTCGGTCGTTGCGCTGCGGCGAGCGGTATCAGCTCACTC
 AAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGAGGAAAGACATGTGAGCAAAAG
 GCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTGTGGCGTTTTTCATAGGCTCCGCCCC
 10 CCTGACGAGCATCAAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAG
 ATACCAGGCGTTTCCCTGGAAGCTCCCTCGTGGCTCTCCTGTTCCGACCTGCCGCTTACCG
 GATACCTGTCCGCTTCTCCCTTCGGGAAGCGTGGCGCTTCTCATAGCTCAGCGTGTAGGTAT
 CTCAGTTCGGTGTAGGTGTTGCTCCAAGCTGGGCTGTGTGCACGAACCCCGCTCAGCCCGA
 CCGCTGCGCCTTATCCGTTAACTATCGTCTTGAGTCCAACCGGTAAAGACAGACTATCGCCAC
 15 TGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGAGGCGGTGTACAGAGTCTTCTG
 AAGTGGTGGCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCC
 AGTTACCTTCGGAAGAGAGTTGGTAGCTCTTGATCCGGCAACCAACACCGCTGGTAGCGGTG
 GTTTTTTTGTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCCTTTGATC
 TTTTCTACGGGTCTGACGCTCAGTGGAAACGAAACTCACGTTAAGGGATTTTGGTCATGAGATT
 20 ATCAAAAAGGATCTTCACTAGATCCTTTAAATTAATAAGTAAATCAATCTAAAGTA
 TATATGAGTAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATC
 TGCTATTTGCTTCATCCATAGTTGCTGACTCCCGTGTGTAGATAACTACGATACGGGAGGG
 CTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCAGCTCAGCGGTCCAGATTAT
 CAGCAATAAACACGAGCAGCGGAGGGCCGAGCGCAGAAGTGGTCTGCACTTTATCCGCTCC
 25 ATCCAGTCTATTAATTTGTTGCCGGGAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCCAA
 CGTTGTTGCCATTGCTGCAAGGCATCGTGGTGTACGCTCGTCTTGGTATGGCTTCATCAGCT
 CCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCATGTTGTGCAAAAAGCGGTAGCTCC
 TTCGTTCTCCGATCGTTGTGAGAAGTAAGTTGGCCGAGTGTATCACTCATGGTTATGCGAGC
 ACTGCATAATTCTTACTGTATGCCATCCGTAAGATGCTTTCTGTGACTGGTGAGTACTCAA
 30 CCAAGTCATTCTGAGAAATAGTGTATGCGGCGACCGAGTGTCTTGGCCGGCTCAACACGGGAT
 AATACCGGCCACATAGCAGAACTTTAAAGTGCTCATATTGGAACGTTCTTCCGGGCGAAA
 ACTCTCAAGGATCTTACCGCTGTGAGATCCAGTTGATGTAACCCACTCGTGACCCAACTGAT
 CTTCAGCATCTTTTACTTTCACAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCA
 35 AAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCTTTTCAATC

DNA sequence PPO115-R1 3878 b.p. complete sequence;

CAGATCTGAGCTTGCCATTGCATACGTTGTATCCATATCATAATATGTACATTTATATGGCTCA
 40 TGTCCAACATTACGCCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGG
 GTCATTAGTTCATAGCCCATATATGGAGTTCGCGTTACATAACTTACGGTAAATGGCCGCTG
 GCTGACCGCCCAACGACCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCA
 ATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTACGGTAAACTGCCACTTGGCAGTACA
 TCAAGTGTATCATATGCCAAGTACGCCCTATTGACGTCAATGACGTAATGGCCGCTGGC
 45 ATTATGCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATC
 GCTATTACCATGGTGATGCGGTTTGGCAGTACATCAATGGCGTGGATAGCGGTTGACTCAG
 GGGATTTCCAAGTCTCCACCCATTGACGTCAATGGGAGTTTGTGTTGGCACCAAAATCAACGGG
 ACTTTCCAAAATGTCGAACAACTCCGCCCATGACGCAATGGGCGTAGGCGTGTACGGTGG
 GAGGTCTATATAAGCAGAGCTCATCTCTGCTCGGGTGGCGCTCTGACATTGTTGTTGTGAC
 50 GTGGGGCCAGATTGCAATCTGTAATAAACTTTTTTTTTCTGAATCCTCAGATTGGCAGTGAG
 AGGAGATTTTGTGCTGGTGTGCTGGCTACTGGGTGGGCGCAGGGATCCGACTGAATCCGT
 AGTACTTCGGTACAACATTTGGGGCTCGTCCGGATACCTCCCATCGGCAGAGTGCCAAC
 GCTTCTTGAACCTTCTTGAACCTCGGCGCGGTGAGTTAAGTACTTGATTTGGTACCTCGCG
 AGGGTTTGGGAGGATCGGAGTGTGGCGGACGCTGCCGGAAGCTCCACCTCCGCTCAGCAGGG
 55 GACGCCCTGACCTGAGCTCTGTGGTATCTGATTGTTGTTGAGCGTCCCTAAGACGGTGATACTA
 AGTCGTGGCTGTGTGTTTGTGTTGCTTGTGTTGTTGCTGCTGTTGTTGCTGACAGCGCTTGG
 AATTGGTGATACCCACACCGCGGCTTGGCAATAACTTTGGAGAGCCTTTTGCCTCCAGTGTG
 TTCGCTGTACTCGTCTCTCTCTCCCTCTCCGGCGCTCTAGAAGTAGTGGATCCCCGGGCTG

CAGGAATTCGATATCAAGCTTATCGATAAGCTCTAGGTCAATGGTTTGACCAGAACATACAAGAG
 CAGTGGGGAATGTGGGAGGGCTCGAGGTCGGGGTCGGCTCTACACATTGTTGTTGTGACGTG
 CGGCCAGATTCCAATCTGTAATAAACCTTTTTTAACTGAATCCTCAGATTGGCAGTGAGAGG
 AGATTTTGTTCGTGGTGTGGCTGGCTACTGGGTGGGCGCAGGGATCGATCCAGACATGATAAG
 5 ATACATTGATGAGTTTGGACAAACCACAAC TAGAATGCAGTGAAAAAATGCTTTATTTGTGAAA
 TTTGTGATGCTATTGCTTTATTTGTAACCATTAATAAGCTGCAATAACAAGTTAACACACAAT
 TGCATTCATTTTATGTTTCAGGTTTCAGGGGAGGTGTGGGAGGTTTTTAAAGCAAGTAAACCT
 CTACAAATCAAGCTGATCCCTGCCTCGCGCTTTCGGTGATGACGGTGAAAACTCTGACACATG
 CAGCTCCCGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCGTCAGGG
 10 CGCGTCAGCGGGTGTGGCGGGTGTGGGGCGCAGCCATGACCCAGTCACGTAGCGATAGCGGAG
 TGTATACTGGCTTAACTATGCCGCATCAGAGCAGATTGTAAGAGTGCACCATATCGGGTGTG
 AAATACCGCACAGATGCGTAAGGAGAAAAATACCGCATCAGGCGCTCTTCGCTTCCTCGCTCACT
 GACTCGCTGCGCTCGGTGCTCGGCTCGGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAAATCG
 GTTATCCACAGAATCAGGGGATAACCGCAGGAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCA
 15 GGAACCGTAAAAAGGCCGCTTGTGGCGTTTTTCCATAGGCTCGGCCCTGACGAGCATCAC
 AAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAGATACCGGCGTTTCC
 CCCTGGAAGCTCCCTCGTGGCTCTCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCT
 TTCTCCCTCGGGAAGCGTGGCGCTTCTCATAGCTCAGCTGTAGGTATCTCAGTTGCGGTAG
 GTCGTTGCTCCAAGCTGGGCTGTGTGCACGAACCCCGTTACGCCGACCGCTGCGCTTATC
 20 CGGTAACATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTG
 GTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGATTCTTGAAGTGGTGGCTAAC
 TACGGCTACACTAGAAGGACAGTATTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAA
 AAGAGTTGGTAGCTCTTGATCCGGCAAACAAACACCGCTGGTAGCGGTGGTTTTTTGTTGCA
 AGCAGCAGATTACGGCAGAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTCTACGGGTCT
 25 GACGCTCAGTGGAAACGAAACTCACGTTAAGGGATTTGGTCATGAGATTATCAAAAAGGATCTT
 CACCTAGATCCTTTTAAATAAAAATGAAGTTTAAATCAATCTAAAGTATATAGGTAACCTT
 GGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCA
 TCCATAGTTGCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCC
 CAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAAGC
 30 CAGCCGGAAGGGCGAGCGCAGAGTGGTCTGCAACTTTATCCGCTCCATCCAGTCTATTAAT
 TGTGCGGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGC
 TGCAGGCATCGTGGTGCACGCTCGTCGTTTGGTATGGCTTCATTGAGCTCCGTTCCCAACGAT
 CAAGGCGAGTTACATGATCCCCATGTTGTGCAAAAAAGCGGTAGCTCCTTCGGTCTCCGATC
 GTTGTGAGAAGTAAGTTGGCCGAGTGTATCACTCATGGTTATGGCAGCACTGCATAATTCTCT
 35 TACTGTGATGCCATCCGTAAGATGCTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAG
 AATAGTGTATCGGCGACCGAGTTGCTCTTGCCGGCGTCAACACGGGATAATACCGCGCCACAT
 AGCAGAACCTTTAAAGTGCTCATCATTTGAAAAAGTTCTTCGGGCGAAAACTCTCAAGGATCTT
 ACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCAACTGATCTTCAGCATCTTTA
 40 CTTTCACCAAGCTTTCTGGGTGAGCAAAACAGGAAGGCAAAATGCCGCAAAAAGGGAATAAGG
 GCGACACGGAAATGTTGAATACTCATACTCTTCTTTTCAAT

Throughout this application, various publications have been
 referenced. The disclosures in these publications are incorporated herein by
 45 reference in order to more fully describe the state of the art.

Appendium of References

Anderson, W.F., Wagner, E.F., and Gilboa, E. 1986. Self-
 50 inactivating retroviral vectors designed for transfer of whole genes into mammalian
 cells. Proc. Natl. Acad. Sci. USA 83:3194-3198.

Boshart,M., Weber,F., Jahn,G., Dorsch-Haesler,K.,
Fleckenstein,B., and Schaffner,W. 1985. A very strong promoter is located
upstream of an immediate early gene of human cytomegalovirus. Cell 41:521-530.

5 Dornburg,R. and Temin,H.M. 1988. Retroviral vector system for
the study of cDNA gene formation. Mol. Cell. Biol. 8:2328-2334.

Dougherty,J.P. and H.M. Temin. 1987. A promoter-less retroviral
vector indicates that there are sequences in U3 required for 3'RNA processing.
10 Proc. Natl. Acad. Sci. USA 84, 1197-1201.

Dougherty,J.P. and Temin,H.M. 1989. New retrovirus helper cells
with almost no nucleotide sequence homology to retrovirus vectors. J.Virol.
63,3209-3212.

15 Embretson,J.E., and H.M.Temin. 1987. Lack of competition results
in efficient packaging of heterologous murine retroviral RNAs and
reticuloendotheliosis encapsidation-minus RNAs by the reticulo-endotheliosis virus
helper cell line. J.Virol. 61,2675-2683.

20 Kewalramani,V.,N., Panganiban,A., and Emerman,M. 1992.
Spleen necrosis virus, an avian immunosuppressive retrovirus, shares a receptor
with the type D simian retroviruses. J. Virol. 66:3026-3031.

25 Markowitz,D., Goff,S., and Bank,A. 1988. A safe packaging line
for gene transfer: separation of viral genes on two different plasmids. J. Virol.
62:1120-1124.

30 P. Olson, H.M.Temin, and R.Dornburg. (1992) Unusually high
frequency of reconstitution of LTRs in U3 minus retrovirus vectors by DNA
recombination or gene conversion. J. Virol. 66:1336-1343

35 W.Sheay, I.Martinez, T.-H.T. Chu, S.Nelson, S.Bhatia, and Ralph
Dornburg (1992) The adenovirus leader sequence enhances gene expression when
inserted d wnstream of various promoters in universal gene expression vectors
(submitted to "Biotechniques).

Temin, H.M. 1986. Retrovirus vectors for gene transfer: efficient integration into and expression of exogenous DNA in vertebrate cell genomes, in "Gene Transfer" (R.Kucherlapati, ed.) Plenum Press, New York.

5 Watanabe, S., and H.M. Temin. 1983. Construction of a helper cell line for avian reticuloendotheliosis virus cloning vectors. *Mol. Cell. Biol.* 3, 2241-2249.

10 Yu, S.-F., Rueden, T., Kantoff, P.W., Garber, C., Seiberg, M., Ruether, U., Anderson, W.F., Wagner, E.F., and Gilboa, E. 1986. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. *Proc. Natl. Acad. Sci.* 83:3194-3198.

15 The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention and all such modifications are intended to be included within the scope of the following claims.

I claim:

1. A recombinant retrovirus vector having a U3-free 5' LTR, a partially deleted 3' LTR, all essential cis-acting sequences for replication, an internal promoter recognizable by a selected host cell, and a non-retroviral gene under the control of the recognized promoter wherein:

(a) the U3-free 5' LTR is positioned 5' of the non-retroviral gene and has a transcriptional promoter and enhancer different from that of the original retroviral promoter and enhancer replacing the original U3 region of the 5'LTR;

(b) the partially deleted 3' LTR is positioned 3' of the non-retroviral gene and has no U3 sequences except for those required at the attachment site for viral integration;

(c) an exogenous polyadenylation addition signal sequence recognized by the selected host cell and positioned on the vector 3' to the 3' LTR viral integration site; and

(d) the internal recognized promoter is positioned adjacent to the non-retroviral gene on the vector to permit expression of the non-retroviral gene in the host cell;

whereby the vector can produce progeny virus in a helper cell with the progeny virus being capable of infecting the selected host cell and forming a provirus in the host cell, with the non-retroviral gene being expressible in the host cell, but the provirus in the host cell will be replication incompetent even in the presence of a helper virus.

2. A retrovirus produced by the recombinant retrovirus vector of claim 1.

3. A host cell containing the provirus of claim 1.

FIGURE 1




A**B**

FIGURE 2

A



B




FIGURE 3




FIGURE 4



INTERNATIONAL SEARCH REPORT

International application No.
PC /US94/06415**A. CLASSIFICATION OF SUBJECT MATTER**IPC(5) : C12N 7/00, 7/01, 15/00, 15/48, 15/85
US CL : 435/69.1, 91.1, 91.4, 172.1, 240.2, 320.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 91.1, 91.4, 172.1, 240.2, 320.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, Dialog, Biosis, Biotech, Medicine, Medline

Search terms: retrovirus, U3, Long terminal repeat, viral vector

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 5,124,263 (TEMIN ET AL.) 23 June 1992, see whole document.	1-3
Y	Journal of Virology, Volume 66, Number 3, issued March 1992, Olson et al., "Unusually High Frequency of Reconstitution of Long Terminal Repeats in U3-Minus Retrovirus Vectors by DNA Recombination or Gene Conversion", pages 1336-1343, see Figures 1 and 2.	1-3

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

Special categories of cited documents:	
A document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
E earlier document published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O document referring to an oral disclosure, use, exhibition or other means	*Z* document member of the same patent family
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

21 JULY 1994

Date of mailing of the international search report

AUG 02 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

DAVID GUZO

Telephone No. (703) 308-0196